Kyla A Mckay

List of Publications by Year
in descending order

34	1,288	394421	377865
papers	citations	19	34
		h-index	g-index

35	35	35	1777
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Health-related quality of life in multiple sclerosis. Neurology, 2016, 86, 1417-1424.	1.1	156
2	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology, 2018, 90, e1316-e1323.	1.1	136
3	Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. NeuroToxicology, 2017, 61, 189-212.	3.0	83
4	Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Multiple Sclerosis and Related Disorders, 2016, 5, 53-65.	2.0	77
5	Comorbidity increases the risk of relapse in multiple sclerosis. Neurology, 2017, 89, 2455-2461.	1.1	77
6	Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. BioMed Research International, 2015, 2015, 1-11.	1.9	76
7	Long-term disability progression of pediatric-onset multiple sclerosis. Neurology, 2019, 92, e2764-e2773.	1.1	69
8	Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. JAMA Neurology, 2019, 76, 1028.	9.0	68
9	Disability worsening among persons with multiple sclerosis and depression. Neurology, 2019, 93, e2216-e2223.	1.1	63
10	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Multiple Sclerosis Journal, 2017, 23, 588-596.	3.0	44
11	Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011â€“2016). Multiple Sclerosis and Related Disorders, 2018, 20, 169-177.	2.0	43
12	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 470-476.	2.0	40
13	Fatigue and Comorbidities in Multiple Sclerosis. International Journal of MS Care, 2016, 18, 96-104.	1.0	38
14	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. International Journal of MS Care, 2018, 20, 76-84.	1.0	35
15	A populationâ€based study comparing multiple sclerosis clinic users and nonâ€users in British Columbia, Canada. European Journal of Neurology, 2016, 23, 1093-1100.	3.3	29
16	Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. Multiple Sclerosis Journal, 2022, 28, 1051-1059.	3.0	29
17	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. Multiple Sclerosis Journal, 2016, 22, 685-693.	3.0	27
18	Determinants of neurological disease: Synthesis of systematic reviews. NeuroToxicology, 2017, 61, 266-289.	3.0	22

#	Article	IF	Citations
19	Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
20	Determinants of quality of life in pediatric- and adult-onset multiple sclerosis. Neurology, 2020, 94, e932-e941.	1.1	20
21	Military service and related risk factors for amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2021, 143, 39-50.	2.1	19
22	Genetic variation associated with the occurrence and progression of neurological disorders. NeuroToxicology, 2017, 61, 243-264.	3.0	18
23	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. Neuroepidemiology, 2018, 51, 1-10.	2.3	18
24	Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 478.	9.0	15
25	Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study. Journal of Neurology, 2019, 266, 481-486.	3.6	13
26	Drug exposure and the risk of multiple sclerosis: A systematic review. Pharmacoepidemiology and Drug Safety, 2018, 27, 133-139.	1.9	8
27	Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse. Annals of Neurology, 2022, 91, 417-423.	5.3	8
28	The systematic search for risk factors in multiple sclerosis. Lancet Neurology, The, 2015, 14, 237-238.	10.2	7
29	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. Neuroepidemiology, 2017, 48, 124-130.	2.3	6
30	Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study. Scientific Reports, 2021, 11, 18528.	3.3	5
31	Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Network Open, 2021, 4, e2136697.	5.9	5
32	Validating the diagnosis of multiple sclerosis using Swedish administrative data in VÃrmland County. Acta Neurologica Scandinavica, 2021, 144, 680-686.	2.1	4
33	Administrative data for observational research in multiple sclerosis: Opportunities and challenges. Multiple Sclerosis Journal, 2022, 28, 3-6.	3.0	2
34	Epidemiology of Multiple Sclerosis and Environmental Risk Factors. , 2021, , 137-153.		0